博茨瓦纳未公开的抗逆转录病毒药物使用情况：对国家估计数的影响。
Undisclosed antiretroviral drug use in Botswana: implication for national estimates.
机构信息
Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana.
Harvard T.H. Chan School of Public Health.
出版信息
AIDS. 2018 Jul 17;32(11):1543-1546. doi: 10.1097/QAD.0000000000001862.
Abstract
: Among 3596 HIV-positive participants enrolled in the Botswana Combination Prevention Project who self-reported no prior antiretroviral (ARV) therapy use and were tested for viral load (n = 951; 27% of all participants), 136 (14%) had HIV-1 RNA less than 400 copies/ml. ARV drugs were detected in 52 (39%) of 134 participants tested. Adjusting for undisclosed ARV use increased the overall estimate of virally suppressed individuals on ARV therapy by 1.4% from 70.2 to 71.6%.
摘要
在博茨瓦纳组合预防项目中，有 3596 名自我报告没有接受过抗逆转录病毒（ARV）治疗且接受病毒载量检测的 HIV 阳性参与者（n=951；占所有参与者的 27%），其中 136 人（14%）的 HIV-1 RNA 小于 400 拷贝/ml。在接受检测的 134 名参与者中，有 52 人（39%）检测到 ARV 药物。调整未公开的 ARV 使用情况后，接受 ARV 治疗的病毒抑制个体的总体估计从 70.2%增加到 71.6%，增加了 1.4%。
相似文献
1
Undisclosed antiretroviral drug use in Botswana: implication for national estimates.博茨瓦纳未公开的抗逆转录病毒药物使用情况：对国家估计数的影响。
AIDS. 2018 Jul 17;32(11):1543-1546. doi: 10.1097/QAD.0000000000001862.
2
Cross-sectional estimates revealed high HIV incidence in Botswana rural communities in the era of successful ART scale-up in 2013-2015.横断面研究结果显示，在 2013-2015 年成功扩大抗逆转录病毒治疗规模的时代，博茨瓦纳农村社区的艾滋病毒发病率很高。
PLoS One. 2018 Oct 24;13(10):e0204840. doi: 10.1371/journal.pone.0204840. eCollection 2018.
3
The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.基线 HIV-1 RNA、耐药性和方案类型作为一线抗逆转录病毒治疗反应决定因素的作用。
J Med Virol. 2014 Oct;86(10):1648-55. doi: 10.1002/jmv.24017. Epub 2014 Jul 11.
4
Short Communication: Assessing Estimates of HIV Incidence with a Recent Infection Testing Algorithm That Includes Viral Load Testing and Exposure to Antiretroviral Therapy.简短通讯：使用一种包括病毒载量检测和抗逆转录病毒治疗暴露情况的近期感染检测算法评估HIV发病率估计值。
AIDS Res Hum Retroviruses. 2018 Oct;34(10):863-866. doi: 10.1089/AID.2017.0316. Epub 2018 Jul 24.
5
High HIV-1 RNA Among Newly Diagnosed People in Botswana.博茨瓦纳新诊断患者中高HIV-1 RNA水平
AIDS Res Hum Retroviruses. 2018 Mar;34(3):300-306. doi: 10.1089/AID.2017.0214. Epub 2018 Jan 17.
6
Progress towards the UNAIDS 95-95-95 targets in the Fifth Botswana AIDS Impact Survey (BAIS V 2021): a nationally representative survey.迈向联合国艾滋病规划署 95-95-95 目标的进展：博茨瓦纳第五次艾滋病影响调查（BAIS V 2021）：一项全国代表性调查。
Lancet HIV. 2024 Apr;11(4):e245-e254. doi: 10.1016/S2352-3018(24)00003-1. Epub 2024 Mar 8.
7
Natural control of HIV infection in young women in South Africa: HPTN 068.南非年轻女性中HIV感染的自然控制：HPTN 068研究
HIV Clin Trials. 2018 Oct;19(5):202-208. doi: 10.1080/15284336.2018.1531534. Epub 2018 Dec 6.
8
A comparison of self-report and antiretroviral detection to inform estimates of antiretroviral therapy coverage, viral load suppression and HIV incidence in Kwazulu-Natal, South Africa.在南非夸祖鲁-纳塔尔省，比较自我报告与抗逆转录病毒检测，以了解抗逆转录病毒治疗覆盖率、病毒载量抑制情况及艾滋病毒发病率的估计值。
BMC Infect Dis. 2017 Sep 29;17(1):653. doi: 10.1186/s12879-017-2740-y.
9
Lack of Virological Suppression Among Young HIV-Positive Adults in Botswana.博茨瓦纳年轻 HIV 阳性成年人中病毒学抑制不足。
J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):557-565. doi: 10.1097/QAI.0000000000001715.
10
Antiretroviral drug use and HIV drug resistance among MSM and transgender women in sub-Saharan Africa.撒哈拉以南非洲地区男男性行为者和跨性别女性中的抗逆转录病毒药物使用和 HIV 耐药性。
AIDS. 2018 Jun 19;32(10):1301-1306. doi: 10.1097/QAD.0000000000001839.
引用本文的文献
1
High prevalence of undisclosed antiretroviral drug use among individuals initiating HIV treatment in Gaborone, Botswana.博茨瓦纳哈博罗内开始接受艾滋病毒治疗的人群中，未披露抗逆转录病毒药物使用情况的比例很高。
Front Public Health. 2025 Jun 5;13:1582940. doi: 10.3389/fpubh.2025.1582940. eCollection 2025.
2
The impact of non-disclosure of HIV status and antiretroviral therapy on HIV recency testing and incidence algorithms.未披露 HIV 状况和抗逆转录病毒疗法对 HIV 近期检测和发病算法的影响。
Vox Sang. 2024 Jun;119(6):581-589. doi: 10.1111/vox.13627. Epub 2024 Apr 15.
3
Archived rilpivirine-associated resistance mutations among ART-naive and virologically suppressed people living with HIV-1 subtype C in Botswana: implications for cabotegravir/rilpivirine use.博茨瓦纳未接受 ART 治疗且病毒学抑制的 HIV-1 亚型 C 感染者中与 rilpivirine 相关的耐药突变的存档：对 cabotegravir/rilpivirine 应用的影响。
J Antimicrob Chemother. 2023 Oct 3;78(10):2489-2495. doi: 10.1093/jac/dkad258.
4
Motivations for blood donation by HIV-positive individuals on antiretrovirals in South Africa: A qualitative study.南非抗逆转录病毒治疗的 HIV 阳性个体献血的动机：一项定性研究。
Transfus Med. 2023 Aug;33(4):277-286. doi: 10.1111/tme.12957. Epub 2023 Feb 17.
5
Doravirine-associated resistance mutations in antiretroviral therapy naïve and experienced adults with HIV-1 subtype C infection in Botswana.博茨瓦纳 HIV-1 亚型 C 感染的抗逆转录病毒治疗初治和经验丰富成人中与多伟拉韦相关的耐药突变。
J Glob Antimicrob Resist. 2022 Dec;31:128-134. doi: 10.1016/j.jgar.2022.08.008. Epub 2022 Aug 13.
6
HIV drug resistance in a community-randomized trial of universal testing and treatment: HPTN 071 (PopART).社区随机化试验中普遍检测和治疗的艾滋病毒耐药性：HPTN 071（PopART）。
J Int AIDS Soc. 2022 Jul;25(7):e25941. doi: 10.1002/jia2.25941.
7
Undisclosed HIV status and antiretroviral therapy use among South African blood donors.南非献血者中未公开的 HIV 状态和抗逆转录病毒治疗的使用情况。
Transfusion. 2021 Aug;61(8):2392-2400. doi: 10.1111/trf.16571. Epub 2021 Jul 5.
8
Undisclosed Antiretroviral Therapy Use at Primary Health Care Clinics in Rural KwaZulu Natal South Africa: A DO-ART Trial Sub-study.南非夸祖鲁-纳塔尔省农村初级卫生保健诊所未公开的抗逆转录病毒治疗使用情况：DO-ART 试验子研究。
AIDS Behav. 2021 Nov;25(11):3695-3703. doi: 10.1007/s10461-021-03319-4. Epub 2021 Jun 7.
9
Pharmacology of HIV Cure: Site of Action.HIV 治愈的药理学：作用部位。
Clin Pharmacol Ther. 2021 Apr;109(4):841-855. doi: 10.1002/cpt.2187. Epub 2021 Mar 5.
10
Rapid emergence of resistance to antiretroviral treatment after undisclosed prior exposure: A case report.未披露的既往暴露后抗逆转录病毒治疗耐药性的快速出现：一例报告
South Afr J HIV Med. 2019 Jul 30;20(1):965. doi: 10.4102/sajhivmed.v20i1.965. eCollection 2019.
本文引用的文献
1
A comparison of self-report and antiretroviral detection to inform estimates of antiretroviral therapy coverage, viral load suppression and HIV incidence in Kwazulu-Natal, South Africa.在南非夸祖鲁-纳塔尔省，比较自我报告与抗逆转录病毒检测，以了解抗逆转录病毒治疗覆盖率、病毒载量抑制情况及艾滋病毒发病率的估计值。
BMC Infect Dis. 2017 Sep 29;17(1):653. doi: 10.1186/s12879-017-2740-y.
2
90-90-90 and ending AIDS: necessary and feasible.90-90-90与终结艾滋病：必要且可行。
Lancet. 2017 Jul 22;390(10092):341-343. doi: 10.1016/S0140-6736(17)31872-X.
3
Association of Implementation of a Universal Testing and Treatment Intervention With HIV Diagnosis, Receipt of Antiretroviral Therapy, and Viral Suppression in East Africa.东非普遍检测与治疗干预措施的实施与HIV诊断、抗逆转录病毒治疗的接受情况及病毒抑制之间的关联
JAMA. 2017 Jun 6;317(21):2196-2206. doi: 10.1001/jama.2017.5705.
4
A universal testing and treatment intervention to improve HIV control: One-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial.一项旨在改善艾滋病毒控制的通用检测与治疗干预措施：赞比亚干预社区在HPTN 071（PopART）整群随机试验中的一年期结果。
PLoS Med. 2017 May 2;14(5):e1002292. doi: 10.1371/journal.pmed.1002292. eCollection 2017 May.
5
Status and methodology of publicly available national HIV care continua and 90-90-90 targets: A systematic review.公开可用的国家艾滋病毒护理连续体及90-90-90目标的现状与方法：一项系统评价。
PLoS Med. 2017 Apr 4;14(4):e1002253. doi: 10.1371/journal.pmed.1002253. eCollection 2017 Apr.
6
Population levels and geographical distribution of HIV RNA in rural Ugandan and Kenyan communities, including serodiscordant couples: a cross-sectional analysis.乌干达和肯尼亚农村社区 HIV RNA 流行水平和地理分布，包括血清不一致的夫妇：一项横断面分析。
Lancet HIV. 2017 Mar;4(3):e122-e133. doi: 10.1016/S2352-3018(16)30220-X. Epub 2016 Dec 16.
7
Undisclosed HIV infection and antiretroviral therapy use in the Kenya AIDS indicator survey 2012: relevance to national targets for HIV diagnosis and treatment.2012年肯尼亚艾滋病指标调查中未披露的艾滋病毒感染情况及抗逆转录病毒疗法的使用：与国家艾滋病毒诊断和治疗目标的相关性
AIDS. 2016 Nov 13;30(17):2685-2695. doi: 10.1097/QAD.0000000000001227.
8
Detectable HIV Viral Load in Kenya: Data from a Population-Based Survey.肯尼亚可检测到的艾滋病毒病毒载量：基于人群调查的数据。
PLoS One. 2016 May 18;11(5):e0154318. doi: 10.1371/journal.pone.0154318. eCollection 2016.
9
Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey.博茨瓦纳在实现 2020 年艾滋病署 90-90-90 抗逆转录病毒治疗和病毒学抑制目标方面的进展：一项基于人群的调查。
Lancet HIV. 2016 May;3(5):e221-30. doi: 10.1016/S2352-3018(16)00037-0. Epub 2016 Mar 24.
10
Clinical outcomes and antiretroviral therapy in 'elite' controllers: a review of the literature.“精英”控制者的临床结局与抗逆转录病毒治疗：文献综述
J Virus Erad. 2015 Apr;1(2):72-77. doi: 10.1016/S2055-6640(20)30488-X.
Zotero 插件